Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions ; volume:73 ; number:2 ; day:27 ; month:1 ; year:2024 ; pages:1-11 ; date:2.2024
Cancer immunology immunotherapy ; 73, Heft 2 (27.1.2024), 1-11, 2.2024
- Classification
-
Medizin, Gesundheit
- Creator
-
Li, Xingchen
Tian, Wenzhi
Jiang, Zhongxing
Song, Yongping
Leng, Xiangyang
Yu, Jifeng
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00262-023-03606-0
- URN
-
urn:nbn:de:101:1-2404291313398.699239761475
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:55 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Li, Xingchen
- Tian, Wenzhi
- Jiang, Zhongxing
- Song, Yongping
- Leng, Xiangyang
- Yu, Jifeng
- SpringerLink (Online service)
Other Objects (12)
Normalization cancer immunotherapy: blocking Siglec-15!
Targeting TIGIT for cancer immunotherapy: recent advances and future directions
Targeting TNFR2 for cancer immunotherapy: recent advances and future directions
Nano‐LYTACs for Degradation of Membrane Proteins and Inhibition of CD24/Siglec‐10 Signaling Pathway
Nano‐LYTACs for Degradation of Membrane Proteins and Inhibition of CD24/Siglec‐10 Signaling Pathway
Targeting CD24 as a novel immunotherapy for solid cancers
Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions
Mesoporous Silica Nanoparticles as an Ideal Platform for Cancer Immunotherapy: Recent Advances and Future Directions.
Recent advances in cancer immunotherapy
Recent advances in cancer immunotherapy
Recent advances in cancer immunotherapy
Advances on immunotherapy for osteosarcoma
Normalization cancer immunotherapy: blocking Siglec-15!
Targeting TIGIT for cancer immunotherapy: recent advances and future directions
Targeting TNFR2 for cancer immunotherapy: recent advances and future directions
Nano‐LYTACs for Degradation of Membrane Proteins and Inhibition of CD24/Siglec‐10 Signaling Pathway
Nano‐LYTACs for Degradation of Membrane Proteins and Inhibition of CD24/Siglec‐10 Signaling Pathway
Targeting CD24 as a novel immunotherapy for solid cancers
Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions
Mesoporous Silica Nanoparticles as an Ideal Platform for Cancer Immunotherapy: Recent Advances and Future Directions.
Recent advances in cancer immunotherapy
Recent advances in cancer immunotherapy
Recent advances in cancer immunotherapy
Advances on immunotherapy for osteosarcoma
Normalization cancer immunotherapy: blocking Siglec-15!
Targeting TIGIT for cancer immunotherapy: recent advances and future directions
Targeting TNFR2 for cancer immunotherapy: recent advances and future directions
Nano‐LYTACs for Degradation of Membrane Proteins and Inhibition of CD24/Siglec‐10 Signaling Pathway
Nano‐LYTACs for Degradation of Membrane Proteins and Inhibition of CD24/Siglec‐10 Signaling Pathway
Targeting CD24 as a novel immunotherapy for solid cancers
Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions
Mesoporous Silica Nanoparticles as an Ideal Platform for Cancer Immunotherapy: Recent Advances and Future Directions.
Recent advances in cancer immunotherapy
Recent advances in cancer immunotherapy
Recent advances in cancer immunotherapy